Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors

PURPOSE: Anaplastic lymphoma kinase (ALK) rearrangement is a well-known driver oncogene in non–small-cell lung cancer and has also been identified in other types of tumors. However, there is limited evidence on the clinical response to ALK tyrosine kinase inhibitors (TKIs), such as alectinib and cri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Takeyasu, Yuki, Okuma, Hitomi S., Kojima, Yuki, Nishikawa, Tadaaki, Tanioka, Maki, Sudo, Kazuki, Shimoi, Tatsunori, Noguchi, Emi, Arakawa, Ayumu, Mori, Taisuke, Sunami, Kuniko, Kubo, Takashi, Kohno, Takashi, Akihiko, Yoshida, Yamamoto, Noboru, Yonemori, Kan
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2021
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8140781/
https://ncbi.nlm.nih.gov/pubmed/34036223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.20.00383
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados